At the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 27 to December 2 in Chicago, USA, Siemens Healthcare is introducing its next-generation Biograph mCT, a PET-CT scanner that enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion).
Technological innovations and intelligent software solutions within the new PET-CT result in quantitative assessments that are reportedly accurate and consistent. Siemens has stated that it "... presents with the new Biograph mCT another paradigm in PET-CT to further strengthen the company’s innovative power and competitiveness within the recently introduced global initiative “Agenda 2013”, previously reported in IMAGING Management.
“By bringing accuracy and reproducibility to quantification in PET, we can more precisely characterize cancer lesions, allowing for better staging and monitoring of the change in activity over time for more accurate assessment of treatment response”, said Jerry Froelich, MD, FACR, Loken Professor of Radiological Sciences and head of molecular imaging and nuclear medicine at the University of Minnesota, Minneapolis. “In cardiology, being able to measure absolute myocardial blood flow allows for accurate assessment of multi-vessel disease. In neurology, the potential is huge. The ability to noninvasively assess the brain can improve the diagnosis and therefore management of patients presenting signs of Alzheimer's disease.”
